Ronaldo Cavalcante's Contact Details

Ronaldo Cavalcante's Company Details

Zambon

Washington, DC, US • 2470 Employees
Major Drugs

Zambon is a chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovating cure & care to improve patients’ lives. Present in Europe, America and Asia with over 2,900 employees and manufacturing units in Italy, Switzerland, France, China and Brazil, in 2023 the Group revenues amounted to 899 million euros. Zambon SpA, the pharma subsidiary of the group with its 23 branchess and products commercialized in 87 countries, has taken a new role in the industry. In addition to pain and diseases of the respiratory system and urological system, Zambon is establishing a global pipeline and introducing important treatments for serious diseases such as Parkinson’s Disease, Cystic Fibrosis, BOS and NCFB. In recent years the Group established ZBiotech, a specialized biotech company that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules. Zambon also produces high quality products thanks to the management of the whole production chain which involves Zach-Zambon Chemicals, a privileged partner for API, custom synthesis and generic products. Zambon complements the offering of medicines with modern health solutions. Through Zcube-Zambon Research Venture it actively scouts and supports the growth of innovative projects and startups. Among them, in 2018 Zcube founded Careapt which develops integrated Hi-Tech/Hi-Touch solutions for chronic disease management. The Zambon group also includes ItaliAssistenza, a Home Care Company involved in the design and delivery of patient support programs (PSP) and home care services. Zambon was established in 1906 in Vicenza and is headquartered in Milan within OpenZone, the scientific campus where knowledge is shared between partners in the field of Healthcare, founded with the aim to transform research into enterprise.